Indegene Ltd — Q1 FY27 earnings call

← Q4 FY26 call · All quarters

Summary generated by AI from the official transcript Indegene Ltd filed with BSE on 17 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries

The short read

At its 28th AGM, Indegene reported FY2025-26 revenue growth of 23.6% to INR35,105 million, crossing INR3,500 crores in annual revenue and INR1,000 crores in a single quarter for the first time. EBITDA grew 11.1% to INR6,247 million while profit after tax was INR4,011 million, with management attributing margin compression to AI investments and integration of its largest acquisition, BioPharm. Management also detailed three completed acquisitions during the year, a reorganization into two segments, and answered shareholder questions on margins, capex, client concentration, and capital allocation.

Numbers mentioned

Revenue: INR35,105 million or USD396.9 million (FY2025-26)

p. 8

“Revenue grew 23.6% to INR35,105 million or USD396.9 million.”

Manish Gupta, page 8 of the filed PDF · View the filing

EBITDA: INR6,247 million (FY2025-26)

p. 8

“EBITDA grew 11.1% to INR6,247 million.”

Manish Gupta, page 8 of the filed PDF · View the filing

Profit after tax: INR4,011 million (FY2025-26)

p. 8

“Profit after tax was INR4,011 million, as our margins deliberately absorbed heavy investments in AI consulting and delivery, together with the integration of our largest acquisition.”

Manish Gupta, page 8 of the filed PDF · View the filing

Operating cash generated: roughly INR650 crores (FY2025-26)

p. 9

“We generated roughly INR650 crores of operating cash, and your board has recommended a final dividend of INR2.25 per share.”

Manish Gupta, page 9 of the filed PDF · View the filing

Revenue per employee: USD75,000 (FY26)

p. 9

“revenue has grown faster than headcount, with revenue per employee growing to USD75,000 by the close of FY '26, the highest among peers.”

Manish Gupta, page 9 of the filed PDF · View the filing

Enterprise Commercial Solutions revenue: INR2,461 crores, grew about 27.0% (FY26)

p. 9

“Enterprise Commercial Solutions, which grew by about 27.0% to INR2,461 crores, and Enterprise Medical Solutions, which grew about 16.0% to INR930 crores.”

Manish Gupta, page 9 of the filed PDF · View the filing

Cash and current investments: INR1,481 crores (FY26)

p. 9

“We remain debt-free with bank balances and current investments of INR1,481 crores.”

Manish Gupta, page 9 of the filed PDF · View the filing

BioPharm acquisition cost: approximately INR882 crores

p. 9

“BioPharm, acquired in October 2025 for approximately INR882 crores, this is our largest acquisition to date.”

Manish Gupta, page 9 of the filed PDF · View the filing

MLR assets reviewed: more than 65,000 (2025)

p. 7

“We have reviewed more than 65,000 MLR assets in 2025.”

Manish Gupta, page 7 of the filed PDF · View the filing

Free cash flow growth: 162% year on year (FY26)

p. 24

“Manish already mentioned the cash flow from operations, the free cash flow grew by 162% year on year, and that was a key factor in deciding on the higher dividend.”

Suhas Prabhu, page 24 of the filed PDF · View the filing

BioPharm acquisition cost in USD: US$104 million

p. 20

“in US dollar terms, the acquisition cost was US$104 million, of which USD65 million was paid at closing.”

Suhas Prabhu, page 20 of the filed PDF · View the filing

Subcontracting and technical fees growth: about 28% growth (FY26)

p. 27

“that has contributed to about 28% growth on our third-party costs.”

Suhas Prabhu, page 27 of the filed PDF · View the filing

Top five customers revenue contribution: about 30.0% of revenues

p. 26

“our top five customers totally constitute about 30.0% of our revenues, and this has consistently been reducing, but as a value, this is growing year on year.”

Suhas Prabhu, page 26 of the filed PDF · View the filing

North America revenue contribution: close to about 74.0% to 75.0%

p. 26

“North America and largely US is the largest geographic segment, close to about 74.0% to 75.0%, followed by Europe, which is the second largest region for our customers with 22.0% revenue contribution”

Suhas Prabhu, page 26 of the filed PDF · View the filing

Total capex: INR246 million (FY26)

p. 25

“our total capex excluding leasehold improvements, which were largely in the nature of computer equipment, compute devices, servers, and the like, was around INR229 million in FY25 and about INR246 million in FY26.”

Suhas Prabhu, page 25 of the filed PDF · View the filing

What management said it would do

A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.

EBITDA margin — 19% to 20% · Q4 of current fiscal year

stated conditionally by Suhas Prabhu

p. 24

“the second half and more specifically Q4 should see our margins get back into that 19% in the range of 19% to 20% at EBITDA margin levels.”

Suhas Prabhu, page 24 of the filed PDF · View the filing

Amortization charge — about INR50 crores every quarter · starting Q3 for four quarters into H2 of next fiscal year

stated firmly by Suhas Prabhu

p. 24

“progressively this would also be lowered starting Q3 by about INR50 crores every quarter and about four quarters into the next, which is H2 of next fiscal year, a further decline in the amortization charge impacting our PAT margins positively”

Suhas Prabhu, page 24 of the filed PDF · View the filing

Capex as percentage of revenue — in the range of 1.0% of revenues · FY27

stated firmly by Suhas Prabhu

p. 25

“we believe that in FY27 our total capex would be in the range of 1.0% of our revenues.”

Suhas Prabhu, page 25 of the filed PDF · View the filing

ECS segment margin — exceed 20% · by Q4 of the current year

stated conditionally by Suhas Prabhu

p. 25

“the margins of this segment at a segmental margin level should exceed 20% and should impact the company margins also positively going into that 19% to 20% range by Q4 of the current year.”

Suhas Prabhu, page 25 of the filed PDF · View the filing

Largest client relationship size — USD75 million · next five years

stated as an aspiration by Manish Gupta

p. 22

“Our largest customer should be crossing USD75 million in this period.”

Manish Gupta, page 22 of the filed PDF · View the filing

Client pyramid - USD50 million client — break into a USD50 million client · next 2 years

stated as an aspiration by Manish Gupta

p. 11

“We break into a USD50 million client, hopefully in the next 2 years.”

Manish Gupta, page 11 of the filed PDF · View the filing

EBITDA margin band — 19.0% to 20.0%

stated as an aspiration by Manish Gupta

p. 13

“EBITDA margins recovering and sustained in that 19.0% to 20.0% band which we used to be earlier.”

Manish Gupta, page 13 of the filed PDF · View the filing

Overall company scale — next five years

stated as an aspiration by Manish Gupta

p. 22

“I would say that we aspire to be much larger than what we are today in the next five years.”

Manish Gupta, page 22 of the filed PDF · View the filing

Q&A highlights

Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.

Management outlined priorities of deepening the client pyramid, continuing AI investment, strengthening people, and improving margins.

Answered by Manish Gupta

Asked by Sarvjeet Singh: What are the company's plans for the next 24 months?

p. 11

“Our first priority is making sure that we progress on this client pyramid, right? We break into a USD50 million client, hopefully in the next 2 years.”

Manish Gupta, page 11 of the filed PDF · View the filing

Management said the company aims to be an industry leader by 2030, tracking indicators like revenue per employee, client base breadth, and margin recovery rather than publishing specific targets.

Answered by Manish Gupta

Asked by Gagan Kumar: What steps are being taken to improve shareholder returns and profitability, and where does the company see itself by 2030?

p. 13

“while we do not publish specific targets, financial targets, but the indicators we would encourage you to track are revenues growing faster than headcount with revenues per employee, a broadening client base”

Manish Gupta, page 13 of the filed PDF · View the filing

Management described a governance process involving an investment subcommittee and board sign-off, but did not give specific quantitative targets.

Answered by Manish Gupta

Asked by Santosh Kumar Saraf: Does the board set measurable ROCE, EBITDA margin, or payback targets when approving acquisitions?

p. 23

“The board continues to look at EBITDA, ROCE, ROE, any acquisition we make, any investment we undertake.”

Manish Gupta, page 23 of the filed PDF · View the filing

Management clarified BioPharm's contribution was smaller than the shareholder assumed and said the company is adequately staffed on AI talent, adding people selectively.

Answered by Manish Gupta

Asked by Jasmeet Singh: How much did BioPharm contribute to last quarter's revenue and does the company have enough AI-skilled headcount?

p. 19

“Our USD397 million revenue last year, out of which approximately 21.5 came from BioPharm, and last quarter itself our revenue was USD112.6 million, right?”

Manish Gupta, page 19 of the filed PDF · View the filing

Management explained margin compression stemmed from front-end investments and a large deal's revenue recognition timing, expecting recovery to the 19-20% range by Q4.

Answered by Suhas Prabhu

Asked by Samrat Sarkar: Why did profitability growth not match revenue growth, and will consolidated operating margins settle at 16%?

p. 24

“there have been two factors that have contributed to the lower margin compared to the past year at EBITDA level.”

Suhas Prabhu, page 24 of the filed PDF · View the filing

Management attributed the rise to BioPharm's higher third-party cost structure and acquisition-related diligence and legal costs.

Answered by Suhas Prabhu

Asked by Samrat Sarkar: Why did subcontracting and technical fees increase 78% in FY26?

p. 27

“This is a business which has about 20% to 22% third-party costs, and therefore as on a combined basis, the proportions have gone up.”

Suhas Prabhu, page 27 of the filed PDF · View the filing

Management said AI is helping the company move upstream into higher-value work and access larger client budgets rather than primarily cutting costs.

Answered by Manish Gupta

Asked by Pramod Kumar Jain: How much cost has AI/GenAI saved and is it helping win new clients?

p. 25

“AI is helping us go upstream as I alluded to earlier, unlock much larger client budgets, existing client budgets”

Manish Gupta, page 25 of the filed PDF · View the filing

Management described a campus recruitment program drawing from life science and engineering backgrounds with an extensive training program after joining.

Answered by Suhas Prabhu

Asked by Manjeet Singh: What is the internship program and how do students fare after it?

p. 26

“About 25% of our new recruits are that's the ratio of campus to the recruits, and about 30% of our overall recruits every year are from the campus programs.”

Suhas Prabhu, page 26 of the filed PDF · View the filing

Risks flagged

Regulated, slow-changing industry could limit pace of adoption of new operating models

p. 22

“we operate in an industry which is highly regulated. It's also slow to change, right?”

Manish Gupta, page 22 of the filed PDF · View the filing

Adoption of new offerings by clients could be slower than anticipated

p. 22

“Today, what we see is customer enthusiasm is real, but, of course, adoption is measured.”

Manish Gupta, page 22 of the filed PDF · View the filing

Pending earn-out liability from BioPharm acquisition due in 2027

p. 20

“there is a pending earn-out payment of USD19 million that is due in 2027.”

Suhas Prabhu, page 20 of the filed PDF · View the filing

Higher amortization charge continuing to impact PAT margins

p. 24

“What we would see still impacting at a PAT level would be the higher amortization charge”

Suhas Prabhu, page 24 of the filed PDF · View the filing

Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.

Continue reading

More Q1 FY27 earnings calls, in alphabetical order